Physician profile
Jon Adleberg
NPI 1710981246
$20,501.34
in general payments reported to CMS, 2019-2025
20 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,493 · 2020: $6,520 · 2021: $964 · 2022: $915 · 2023: $1,138 · 2024: $876 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,609.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardinal Health 108 LLC | $15,088.76 | 2019-2020 | |
| Alimera Sciences, INC. | $812.89 | 2019-2024 | Iluvien, Yutiq |
| Genentech USA, INC. | $703.84 | 2019-2025 | Vabysmo |
| Mallinckrodt Hospital Products INC. | $664.14 | 2020-2025 | Acthar |
| Apellis Pharmaceuticals, INC. | $656.56 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $427.13 | 2019-2024 | Eylea, Eylea Hd |
| Abbvie INC. | $382.50 | 2022-2025 | Ozurdex |
| Novartis Pharmaceuticals Corporation | $345.41 | 2019-2021 | |
| Biogen, INC. | $342.29 | 2022-2024 | Byooviz |
| Coherus Oncology, INC. | $235.23 | 2022-2024 | |
| Astellas Pharma US INC | $206.99 | 2023-2025 | Izervay |
| Sandoz INC. | $150.96 | 2024-2025 | Cimerli |
| Bausch & Lomb Americas INC. | $148.27 | 2023 | Xipere |
| Eyepoint US, INC. | $90.21 | 2021-2022 | |
| Alcon Vision LLC | $57.07 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $55.04 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $41.44 | 2025 | Yutiq, Iluvien |
| Glaxosmithkline, LLC. | $38.64 | 2025 | Ojjaara |
| Harrow Eye, LLC | $28.96 | 2024 | Triesence, Iheezo |
| Vyera Pharmaceuticals, LLC | $25.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Adleberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.